Want to see LFCR full AI Analyst Report?
Top Page
Lifecore Biomedical
(NASDAQ:LFCR)
Select Model
Select Model
Rating:51Neutral
Price Target:
$4.50
▲(3.93% Upside)
Action:Reiterated
Date:06/06/26
The score is primarily held back by weak financial performance—ongoing net losses and very high leverage—despite a rebound to positive operating/free cash flow. Technicals are supportive in the near term (price above short-term averages and positive MACD), but overbought readings and weaker long-term trend caps upside, while valuation remains unattractive/unclear due to negative earnings and no dividend yield.
Positive Factors
Specialized CDMO model
Lifecore’s focus on sterile injectable development and fill-finish services is a durable, high-barrier niche. Injectable biologics and parenterals require specialized facilities, regulatory know-how and quality systems, supporting client stickiness, recurring contract work and long sales cycles that favor incumbents.
Negative Factors
High leverage
Very high debt relative to equity meaningfully constrains financial flexibility. Elevated leverage raises refinancing and interest-rate sensitivity, limits ability to invest in capacity or weather customer timing variability, and increases the risk that cash generation must prioritize debt service over growth.
Read all positive and negative factors
Positive Factors
Negative Factors
Specialized CDMO model
Lifecore’s focus on sterile injectable development and fill-finish services is a durable, high-barrier niche. Injectable biologics and parenterals require specialized facilities, regulatory know-how and quality systems, supporting client stickiness, recurring contract work and long sales cycles that favor incumbents.
Read all positive factors
Lifecore Biomedical (LFCR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$165.79M
Dividend YieldN/A
Average Volume (3M)201.38K
Price to Earnings (P/E)―
Beta (1Y)1.79
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees382
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-1.03
Shares Outstanding37,509,407
10 Day Avg. Volume134,576
30 Day Avg. Volume201,379
Financial Highlights & Ratios
PEG Ratio0.32
Price to Book (P/B)-19.16
Price to Sales (P/S)2.10
P/FCF Ratio43.67
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$6.50Price Target Upside50.12% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.05
Revenue Forecast (FY)$122.18M
Lifecore Biomedical Business Overview & Revenue Model
Company Description
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides service...
How the Company Makes Money
Lifecore Biomedical makes money primarily by providing fee-for-service CDMO work to pharmaceutical and biotechnology customers, generating revenue when it performs contracted development, manufacturing, and fill-finish activities for customer-owne...
Lifecore Biomedical Earnings Call Summary
Earnings Call Date:Mar 16, 2026
(Q5-2025)
| % Change Since: |
Next Earnings Date:Aug 05, 2026
Earnings Call Sentiment Positive
The call conveys a generally positive tone: strong revenue growth (+26%), a meaningful adjusted EBITDA turnaround (to $3.1M), substantial SG&A reductions (~$5.9M), and multiple commercial and pipeline milestones (new wins, quality audits, automation/validation progress). Offsetting these positives are continued GAAP losses ($10M), a decline in CDMO gross profit driven by product mix and lower development revenue, reliance on a large customer's 2027 inflection and multi-year timelines for commercial site transfers, and remaining work to reach the company's 25% adjusted EBITDA margin target. On balance the operational progress, improved profitability on an adjusted basis, and new business momentum outweigh the near-term challenges and timing risks.Positive Updates
Strong Revenue Growth
Revenue for the 3 months ended Sept 30, 2025 was $31.1M, a 26% increase versus $24.7M in the comparable prior period. The increase was driven primarily by a $4.8M rise in HA manufacturing revenues and $1.6M increase in CDMO revenues (higher sales volumes of $2.6M partially offset by lower development revenue).
Negative Updates
Continued Net Loss
Reported net loss of $10.0M (loss per diluted share $0.29) for the quarter, improved from $16.2M ($0.53) but the company remains unprofitable on a GAAP basis.
Read all updates
Q5-2025 Updates
Positive
Negative
Strong Revenue Growth
Revenue for the 3 months ended Sept 30, 2025 was $31.1M, a 26% increase versus $24.7M in the comparable prior period. The increase was driven primarily by a $4.8M rise in HA manufacturing revenues and $1.6M increase in CDMO revenues (higher sales volumes of $2.6M partially offset by lower development revenue).
Read all positive updates
Company Guidance
Management reaffirmed transition-period guidance for May 26–Dec 31, 2025 of revenue $74–$76M, net loss of $18.4–$16.4M and adjusted EBITDA of $12–$14M; they also outlined remaining-Q4 guidance of $34–$36M (≈$35M midpoint, ~8% y/y) after estimated June revenue of $8.7M (CDMO $6.6M; HA $2.1M) and YTD (through Sept 30) stub revenue of ≈$39.8M. June adjusted EBITDA was ≈$1.5M, leaving YTD adj. EBITDA ≈$4.6M and implied Q4 adj. EBITDA guidance of $7–$9M (≈$8M midpoint), which produces an implied stub-period adjusted EBITDA margin of roughly 17% at the midpoint (vs. Q3’s ~10%: $3.1M adj. EBITDA on $31.1M revenue); management continues to target a midterm adjusted EBITDA margin of 25% and expects calendar‑2026 revenue to be weighted ~45% H1 / ~55% H2.Lifecore Biomedical Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
18
Very Negative
Cash Flow
56
Neutral
| Breakdown | TTM | Dec 2025 | May 2025 | May 2024 | Aug 2023 | May 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 135.16M | 129.46M | 128.87M | 128.26M | 103.27M | 111.27M |
| Gross Profit | 42.13M | 40.61M | 40.30M | 41.85M | 27.98M | 39.07M |
| EBITDA | -1.03M | 8.24M | -8.81M | 35.60M | -33.17M | 12.84M |
| Net Income | -34.09M | -30.79M | -38.72M | 12.01M | -99.56M | -116.72M |
Balance Sheet | ||||||
| Total Assets | 225.50M | 232.18M | 239.34M | 253.96M | 253.54M | 274.70M |
| Cash, Cash Equivalents and Short-Term Investments | 20.80M | 17.47M | 8.27M | 8.46M | 19.09M | 991.00K |
| Total Debt | 150.14M | 142.61M | 130.82M | 133.57M | 112.62M | 247.78M |
| Total Liabilities | 204.72M | 246.38M | 238.01M | 242.65M | 257.77M | 186.88M |
| Stockholders Equity | 20.78M | -14.20M | 1.34M | 11.31M | -4.23M | 87.82M |
Cash Flow | ||||||
| Free Cash Flow | 10.47M | 6.23M | -13.62M | -18.14M | -38.92M | -52.53M |
| Operating Cash Flow | 17.38M | 12.57M | -206.00K | 257.00K | -17.44M | -22.59M |
| Investing Cash Flow | 3.09M | 10.81M | -6.42M | -18.39M | -4.81M | 79.96M |
| Financing Cash Flow | -5.09M | -7.59M | 6.42M | 7.51M | 39.70M | -57.02M |
Lifecore Biomedical Technical Analysis
Negative
4.33
Price Trends
5.04
Negative
4.90
Negative
6.24
Negative
Market Momentum
-0.20
Positive
33.85
Neutral
5.68
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LFCR, the sentiment is Negative. The current price of 4.33 is below the 20-day moving average (MA) of 4.61, below the 50-day MA of 5.04, and below the 200-day MA of 6.24, indicating a bearish trend. The MACD of -0.20 indicates Positive momentum. The RSI at 33.85 is Neutral, neither overbought nor oversold. The STOCH value of 5.68 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for LFCR.
Lifecore Biomedical Risk Analysis
Lifecore Biomedical disclosed 30 risk factors in its most recent earnings report. Lifecore Biomedical reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Lifecore Biomedical Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | $696.31M | 6.65 | -38.88% | ― | 13.80% | ― | |
53 Neutral | $100.09M | -13.51 | -28.75% | ― | 2.08% | -106.57% | |
52 Neutral | $175.40M | -16.95 | -35.57% | ― | 15.00% | 3.18% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $165.79M | -4.80 | -159.08% | ― | ― | ― | |
45 Neutral | $401.85M | -3.77 | -29.40% | ― | 610.96% | -18.43% |
* Healthcare Sector Average
LFCR
Lifecore Biomedical
4.42
-2.99
-40.35%
IRWD
Ironwood Pharma
4.23
3.48
464.00%
CPIX
Cumberland Pharmaceuticals
6.68
2.67
66.58%
SXTC
China SXT Pharmaceuticals
0.06
-236.94
-99.97%
DERM
Journey Medical Corp
6.37
-0.77
-10.78%
BIOA
BioAge Labs, Inc.
9.04
4.62
104.52%
Lifecore Biomedical Corporate Events
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Lifecore Shareholders Approve New 2026 Stock Incentive Plan
Positive
Jun 5, 2026
At its annual meeting on June 4, 2026, Lifecore Biomedical shareholders approved a new 2026 Stock Incentive Plan that will take effect on Oct. 16, 2026, replacing the company’s 2019 plan and authorizing 2.5 million new shares plus any forfei...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.